Team:UC Davis/Criteria
From 2012.igem.org
Ckdeniston (Talk | contribs) |
|||
Line 1,205: | Line 1,205: | ||
<ul> | <ul> | ||
<li><b>Demonstrate that at least one new BioBrick Part or Device of your own design and construction works as expected; characterize the operation of your new part/device.</b></li> | <li><b>Demonstrate that at least one new BioBrick Part or Device of your own design and construction works as expected; characterize the operation of your new part/device.</b></li> | ||
- | We developed a <a href="http://partsregistry.org/Part:BBa_K936035">strain</a> of <i>E. coli</i>, called E-15 EG3, that can degrade ethylene glycol more efficiently than previous strains could. We created this strain through <a href="https://2012.igem.org/Team:UC_Davis/Project/Directed_Evolution#Liquid">directed evolution</a>, and we found that by repassaging the strain over 25 generations, we were able to increase growth rate on ethylene glycol. | + | We developed a <a href="http://partsregistry.org/Part:BBa_K936035">strain</a> of <i>E. coli</i>, called E-15 EG3, that can degrade ethylene glycol more efficiently than previous strains could. We created this strain through <a href="https://2012.igem.org/Team:UC_Davis/Project/Directed_Evolution#Liquid">directed evolution</a>, and we found that by repassaging the strain over 25 generations, we were able to increase growth rate on ethylene glycol. An increase of 74.8% and 227.84% respectively was observed when compared to the original strain. |
<br><br> | <br><br> | ||
<li><b>Enter this information and other documentation on the part's 'Main Page' section of the Registry.</b></li> | <li><b>Enter this information and other documentation on the part's 'Main Page' section of the Registry.</b></li> |
Revision as of 01:11, 4 October 2012
Comments for the Judges
First we want to thank you for taking the time to look over our wiki. We've put a lot of time into it and would like to highlight the areas we think are particularly noteworthy.Our Human Practices page details both a lesson plan for introducing high school students to the concepts of Synthetic Biology as well as a well written economic toolkit for other iGEM teams to utilize in order to assess the practicality and economic viability of their own projects.
Judging Criteria
Silver Gold
Our team was registered at the start of summer, everyone had a wonderful time working on the project, and we are eager to present at Stanford in October!
This form has been completed and we have added this page to our wiki to further elaborate.
We have created this wiki, which describes our work, parts and results. For more information concerning our project please view our Project page. Additionally we have detailed 19 new parts, as well as sent in DNA of 7 of those parts into the Registry of Standard Biological Parts along with their appropriate sequences and data.
We plan to present both a poster and a talk at the regional Jamboree in Stanford on Oct. 12-14, 2012.
We have entered information detailing 19 new BioBrick parts, both with DNA sequences and data into the Registry. For more information about these parts please view our Parts page
We have submitted DNA for 7 new parts to the Registry, specifically Bba_K936000, Bba_K936013, Bba_K936016, Bba_K936017, Bba_K936020, Bba_K936021, and Bba_K936024. We also submitted our ethylene-glycol degrading strain E-15 EG3, Bba_K936035 to the registry in the form of a glycerol stock. We chose to only send the samples that we had absolute confidence in and we plan to have the remaining planned parts along with our LC Cutinase mutants sent to the Registry as soon as possible.
We also developed an economic toolkit that addresses the ownership, sharing, and innovation aspect of the human practices requirement. By conducting an in-depth analysis of the intellectual property, legal issues that arise, and their relation to the iGEM competition, teams reading our deliverable will hopefully gain a cohesive understanding of the importance of protecting innovation.
A full description of our human practice advances can be found on our Human Practices page.